Notice2021-20727
Agency Information Collection Activities: Proposed Collection; Comment Request
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
September 24, 2021
Issuing agencies
Health and Human Services DepartmentCenters for Medicare & Medicaid Services
Abstract
The Centers for Medicare & Medicaid Services (CMS) is announcing an opportunity for the public to comment on CMS' intention to collect information from the public. Under the Paperwork Reduction Act of 1995 (the PRA), federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information (including each proposed extension or reinstatement of an existing collection of information) and to allow 60 days for public comment on the proposed action. Interested persons are invited to send comments regarding our burden estimates or any other aspect of this collection of information, including the necessity and utility of the proposed information collection for the proper performance of the agency's functions, the accuracy of the estimated burden, ways to enhance the quality, utility, and clarity of the information to be collected, and the use of automated collection techniques or other forms of information technology to minimize the information collection burden.
Full Text
<html>
<head>
<title>Federal Register, Volume 86 Issue 183 (Friday, September 24, 2021)</title>
</head>
<body><pre>
[Federal Register Volume 86, Number 183 (Friday, September 24, 2021)]
[Notices]
[Pages 53060-53061]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2021-20727]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[Document Identifiers: CMS-10786 and CMS-R-153]
Agency Information Collection Activities: Proposed Collection;
Comment Request
AGENCY: Centers for Medicare & Medicaid Services, Health and Human
Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Medicare & Medicaid Services (CMS) is
announcing an opportunity for the public to comment on CMS' intention
to collect information from the public. Under the Paperwork Reduction
Act of 1995 (the PRA), federal agencies are required to publish notice
in the Federal Register concerning each proposed collection of
information (including each proposed extension or reinstatement of an
existing collection of information) and to allow 60 days for public
comment on the proposed action. Interested persons are invited to send
comments regarding our burden estimates or any other aspect of this
collection of information, including the necessity and utility of the
proposed information collection for the proper performance of the
agency's functions, the accuracy of the estimated burden, ways to
enhance the quality, utility, and clarity of the information to be
collected, and the use of automated collection techniques or other
forms of information technology to minimize the information collection
burden.
DATES: Comments must be received by November 23, 2021.
ADDRESSES: When commenting, please reference the document identifier or
OMB control number. To be assured consideration, comments and
recommendations must be submitted in any one of the following ways:
1. Electronically. You may send your comments electronically to
<a href="http://www.regulations.gov">http://www.regulations.gov</a>. Follow the instructions for ``Comment or
Submission'' or ``More Search Options'' to find the information
collection document(s) that are accepting comments.
2. By regular mail. You may mail written comments to the following
address: CMS, Office of Strategic Operations and Regulatory Affairs,
Division of Regulations Development, Attention: Document Identifier/OMB
Control Number: __, Room C4-26-05, 7500 Security Boulevard, Baltimore,
Maryland 21244-1850.
To obtain copies of a supporting statement and any related forms
for the proposed collection(s) summarized in this notice, you may make
your request using one of following:
1. Access CMS' website address at <a href="https://www.cms.gov/Regulations-and-Guidance/Legislation/PaperworkReductionActof1995/PRA-Listing.html">https://www.cms.gov/Regulations-and-Guidance/Legislation/PaperworkReductionActof1995/PRA-Listing.html</a>.
FOR FURTHER INFORMATION CONTACT: William N. Parham at (410) 786-4669.
SUPPLEMENTARY INFORMATION:
Contents
This notice sets out a summary of the use and burden associated
with the following information collections. More detailed information
can be found in each collection's supporting statement and associated
materials (see ADDRESSES).
CMS-10786 Substance Use-Disorder Prevention that Promotes Opioid
Recovery and Treatment (SUPPORT) for Patients and Communities Act
Section 1003 Demonstration Evaluation
CMS-R-153 Medicaid Drug Use Review (DUR) Program
Under the PRA (44 U.S.C. 3501-3520), federal agencies must obtain
approval from the Office of Management and Budget (OMB) for each
collection of information they conduct or sponsor. The term
``collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA requires federal agencies
to publish a 60-day notice in the Federal Register concerning each
proposed collection of information, including each proposed extension
or reinstatement of an existing collection of information, before
submitting the collection to OMB for approval. To comply with this
requirement, CMS is publishing this notice.
Information Collection
1. Type of Information Collection Request: New collection (Request
for a new OMB Control Number); Title of Information Collection:
Substance Use-Disorder Prevention that Promotes Opioid Recovery and
Treatment
[[Page 53061]]
(SUPPORT) for Patients and Communities Act Section 1003 Demonstration
Evaluation; Use: Section 1003 of the SUPPORT Act authorizes the
Secretary of HHS, in consultation with the Director of the Agency for
Healthcare Research and Quality (AHRQ) and the Assistant Secretary for
Mental Health and Substance Use from the Substance Abuse and Mental
Health Services Administration (SAMHSA), to conduct a 54-month
demonstration project (hereinafter, ``the Demonstration'') which is
designed to increase the capacity of Medicaid providers to deliver
substance use disorder (SUD) treatment and recovery services.
Section 1003 also requires an evaluation of the demonstration. The
evaluation is designed to assess:
<bullet> The effectiveness of the Demonstration in increasing the
capacity of providers participating under the Medicaid state plan (or a
waiver of such plan) to provide substance use disorder treatment or
recovery services under such plan (or waiver);
<bullet> The activities carried out under the planning grants and
demonstration project;
<bullet> The extent to which participating states have achieved the
stated goals; and
<bullet> The strengths and limitations of the planning grants and
demonstration project.
This collection of information request is intended to satisfy the
reporting requirements, defined in the statute, regarding the impact of
the Demonstration. The evaluation of the Demonstration will assess the
extent to which the participating states achieved the goals they
established to increase substance use treatment or recovery provider
capacity under the Medicaid program. This includes both the planning
and post-planning periods of the demonstration, as evaluation during
both phases will enable CMS and stakeholders to assess the effects of
the additional support provided to states during the post-planning
period, relative to the planning period only.
Primary data collection will occur in two rounds in year two and
year four of the evaluation. In both rounds, data collection will
consist of: (1) A survey of providers in all 15 Planning Grant states
who are eligible to prescribe and/or administer either buprenorphine or
methadone medication for opioid use disorder (OUD), and (2) focus
groups of providers in five post-planning period states (two focus
groups per state, with six to eight participants in each group) who
treat SUD, including OUD.
The survey will gather information on provider experiences related
to Medicaid provider enrollment, SUD service delivery, and changes in
OUD medication treatment, including barriers and enablers of
prescribing and dispensing.
The focus groups will examine the impact of key aspects of
implementation, such as perceived burdens associated with Medicaid
enrollment or MAT delivery, access to referral placements, value of
state-provided TA, and benefits and unanticipated outcomes experienced
by providers during the Demonstration.
Form Number: CMS-10786 (OMB control number: 0938-NEW); Frequency:
Biennial; Affected Public: Private sector (Business or other for-
profits and Not-for-profit institutions); Number of Respondents:
28,810; Total Annual Responses: 14,405; Total Annual Hours: 3,689. (For
policy questions regarding this collection contact Melanie Brown at
410-786-1095.)
2. Type of Information Collection Request: Revision of a currently
approved collection; Title of Information Collection: Medicaid Drug Use
Review (DUR) Program; Use: States must provide for a review of drug
therapy before each prescription is filled or delivered to a Medicaid
patient. This review includes screening for potential drug therapy
problems due to therapeutic duplication, drug-disease
contraindications, drug-drug interactions, incorrect drug dosage or
duration of drug treatment, drug-allergy interactions, and clinical
abuse/misuse. Pharmacists must make a reasonable effort to obtain,
record, and maintain Medicaid patient profiles. These profiles must
reflect at least the patient's name, address, telephone number, date of
birth/age, gender, history, e.g., allergies, drug reactions, list of
medications, and pharmacist's comments relevant to the individual's
drug therapy.
The States must conduct RetroDUR which provides for the ongoing
periodic examination of claims data and other records in order to
identify patterns of fraud, abuse, inappropriate or medically
unnecessary care. Patterns or trends of drug therapy problems are
identified and reviewed to determine the need for intervention activity
with pharmacists and/or physicians. States may conduct interventions
via telephone, correspondence, or face-to-face contact.
Annual reports are submitted to CMS for the purposes of monitoring
compliance and evaluating the progress of States' DUR programs. The
information submitted by States is reviewed and results are compiled by
CMS in a format intended to provide information, comparisons, and
trends related to States' experiences with DUR. States benefit from the
information and may enhance their programs each year based on State
reported innovative practices that are compiled by CMS from the DUR
annual reports.
In this 2021 collection of information request, we revised certain
FFS, MCO, and Abbreviated MCO survey questions. While a few questions
were added to the surveys to address GAO (U.S. Government
Accountability Office) recommendations, other aspects of the survey
changes include grammar and formatting edits. Overall, we are not
revising our currently approved burden estimates.
Form Number: CMS-R-153 (OMB control number: 0938-0659); Frequency:
Yearly, quarterly, and occasionally; Affected Public: State, Local, or
Tribal Governments; Number of Respondents: 51; Total Annual Responses:
663; Total Annual Hours: 41,004. (For policy questions regarding this
collection contact Mike Forman at 410-786-2666.)
Dated: September 21, 2021.
William N. Parham, III,
Director, Paperwork Reduction Staff, Office of Strategic Operations and
Regulatory Affairs.
[FR Doc. 2021-20727 Filed 9-23-21; 8:45 am]
BILLING CODE 4120-01-P
</pre></body>
</html>Indexed from Federal Register on September 24, 2021.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.